
Australian IT Spending Set to Boost Microsoft Ecosystem
Enterprises in Australia aren't just adopting cloud, they're demanding strategic outcomes from it. They are constantly looking for ways to improve cloud visibility, predictability and cost control.
The 2025 ISG Provider Lens™ Microsoft AI and Cloud Ecosystem report for Australia finds that technology spending in the country is poised for faster growth after several years of caution amid macroeconomic uncertainty. Enterprises are expected to invest mainly in cybersecurity, cloud-enabled digital transformation and infrastructure modernization, including replacement of Windows 10 hardware. At the same time, Australian enterprises are turning to Microsoft-aligned solutions to address cyber risks and aging infrastructure and realize greater return on digital investments.
'Enterprises in Australia aren't just adopting cloud, they're demanding strategic outcomes from it,' said Ben Rossiter, lead, tech modernization, for ISG in Australia. 'They are constantly looking for ways to improve cloud visibility, predictability and cost control.'
These efforts are driving demand for solutions and services that can enhance cloud utilization, cost optimization, governance, security and other capabilities, the report says. Ultimately, companies want the cloud to deliver more measurable business outcomes, especially with ongoing concerns about economic trends and the threat of inflation.
With the rise of remote and hybrid work modes, Australian enterprises are stepping up efforts to improve employee experience, retention and productivity, ISG says. Companies are looking for ways to use Microsoft Teams, SharePoint and OneDrive to enhance collaboration. While still focused on AI, employers are now exploring how to use it to augment human productivity rather than replace workers. Providers are introducing services to help clients create better workplace experiences by tapping into existing data.
Demand for FinOps and related services is growing in Australia as margin pressures lead organizations to increase oversight of IT projects and cloud services, the report says. While cloud-based pay-as-you-go models let companies reduce infrastructure spending, maximizing their value requires cost optimization and predictability. Enterprises are working with providers to better manage Microsoft 365 and Copilot licensing costs, and demand is growing for tailored solutions based on industry-focused blueprints and accelerators.
As Australian companies deploy hybrid clouds, they are aligning technology investments with rising regulatory expectations, including data privacy, cybersecurity standards and AI ethics. Unified security management, compliance and risk mitigation are business imperatives.
'Cyber threats continue to escalate, and Australian enterprises are responding with a sharper focus on prevention, detection and resilience,' said Jan Erik Aase, partner and global leader, ISG Provider Lens Research. 'AI is becoming a critical enabler for improving response speed, decision quality and control of IT environments.'
The report also examines other Microsoft AI and cloud trends affecting enterprises in Australia, including the evolution of Microsoft's AI tools from pilots to production and the growing demand for Microsoft solutions to manage and reduce carbon footprints.
For more insights into the Microsoft-related challenges facing enterprises in Australia, along with ISG's advice for overcoming them, see the ISG Provider Lens™ Focal Points briefing here.
The 2025 ISG Provider Lens™ Microsoft AI and Cloud Ecosystem report for Australia evaluates the capabilities of 39 providers across four quadrants: Managed Services for Azure, Microsoft 365 Services, Power Platform Services and AI Services for Microsoft Clouds.
The report names Accenture & Avanade, DXC Technology, Fujitsu, Kyndryl, TCS and Wipro as Leaders in all four quadrants. It names Capgemini, HCLTech and Telstra as Leaders in three quadrants each. IBM, Infosys, Logicalis, Unisys and Velrada are named as Leaders in two quadrants each. Barhead Solutions, an Akkodis company; Macquarie Cloud Services and NTT DATA are named as Leaders in one quadrant each.
In addition, NTT DATA is named as a Rising Star — a company with a 'promising portfolio' and 'high future potential' by ISG's definition — in two quadrants. Tech Mahindra is named as a Rising Star in one quadrant.
A customized version of the report is available from Barhead Solutions, an Akkodis company.
In the area of customer experience, HCLTech is named the global ISG CX Star Performer for 2025 among Microsoft Cloud Ecosystem Providers. HCLTech earned the highest customer satisfaction scores in ISG's Voice of the Customer survey, part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry.
The 2025 ISG Provider Lens™ Microsoft AI and Cloud Ecosystem report for Australia is available to subscribers or for one-time purchase on this webpage.
About ISG Provider Lens™ Research
The ISG Provider Lens™ Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage.
About ISG
ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
NEXEN TYRE AUSTRALIA Accelerates Growth in SUV and Ute Market with Launch of ROADIAN ATX
Strengthening presence through localised product offerings, enhanced logistics infrastructure, and strategic sports marketing initiatives SEOUL, South Korea, Aug. 18, 2025 /PRNewswire/ -- NEXEN TYRE, a leading global tyre manufacturer, has officially launched the 'ROADIAN ATX' in the Australian market, intensifying its efforts to tap into the country's robust demand for high-inch tyres used on SUVs and Utes. Specifically engineered for both on- and off-road performance, the ROADIAN ATX is optimised for Australia's diverse driving conditions – from desert highways and mountainous terrain to unpaved outback trails and coastal roads. The tyre features a wide contact patch and advanced rubber compound to maximise mileage and tread durability. Key off-road technologies feature a 3D kerf design that enhances wet grip and a Three-Peak Mountain Snowflake (3PMSF) certification, validating its outstanding performance in snowy environments. Additional features such as stone ejectors and side biters prevent gravel retention and enhance traction on rocky surfaces, giving Australian drivers greater durability and confidence in challenging conditions. The introduction of the ROADIAN ATX aligns with NEXEN TYRE's broader strategy to cater to the growing preference for larger vehicles in Australia. The tyre is currently supplied as OE (Original Equipment) for iconic Jeep models including the Wrangler and Gladiator, reinforcing the brand's global credibility and technological leadership. To support its expansion, NEXEN TYRE AUSTRALIA is reinforcing its logistics and sales network across Australia. Following the opening of distribution centres in New South Wales (2023) and Victoria (2024), the company plans to open an additional logistics hub in Queensland in the second half of 2025. These investments aim to provide deliver efficiency and customer service across the eastern economic corridor, including Sydney, Melbourne, and Brisbane. NEXEN TYRE AUSTRALIA is also amplifying its brand visibility through strategic sports marketing. Since October 2024, the company has been the official sponsor of Sydney FC, a leading club in Australia's A-League. The partnership has significantly elevated the brand's profile through LED signage, stadium displays, and virtual advertising during national broadcast matches and global streaming on Paramount+. Furthermore, NEXEN TYRE AUSTRALIA actively engages with local fans through Sydney FC's digital channels, including social media campaigns and newsletter placements, fostering stronger connections with Australian consumers. "The ROADIAN ATX reflects our commitment understanding and meeting the unique needs of the Australian market," said John Bosco (Hyeon Suk) Kim, CEO of NEXEN TYRE. "We will continue to build a strong local presence through product localisation, strategic partnerships, and an enhanced logistics framework." About NEXEN TYRE NEXEN TYRE, established in 1942, is a global tyre manufacturer headquartered in South Korea. NEXEN TYRE, one of the world's fastest growing tyre manufacturers, currently interacts with approximately 150 countries around the world and owns four manufacturing plants – two in Korea (Yangsan and Changnyeong) and one in Qingdao, China. Another plant in Žatec, the Czech Republic has also begun operation in 2019. NEXEN TYRE produces tyresfor passenger cars, SUVs, and light trucks with advanced technology and excellence in design. NEXEN TYRE supplies OE tyresto global premium car makers in various countries around the world proving its quality and technology of its products. Additionally, the company achieved a grand slam of the world's top 4 design awards in 2014 for the first time amongst the various tyre makers in the world. For more information, please visit Press contact: Youngjun LeeCorporate Communication Teamyjlee@ Danbee JungCorporate Communication Teamdbjung@ View original content to download multimedia: SOURCE NEXEN TYRE Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid
We recently published . Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best healthcare stocks. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company integrating artificial intelligence (AI), machine learning, and high-throughput biology to accelerate drug discovery, with a focus on oncology and rare diseases. Its proprietary Recursion OS platform streamlines therapeutic identification and development. In July–August 2025, the company acquired full rights to REV102, an oral ENPP1 inhibitor from Rallybio, aimed at treating hypophosphatasia (HPP), a rare genetic disorder with no approved oral disease-modifying therapies. This acquisition expands Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s rare disease pipeline and gives it full control over a promising preclinical program. At the same time, the business streamlined its portfolio by discontinuing or pausing several programs, narrowing its focus to six active candidates, four in oncology and two in rare diseases. Its innovative AI-driven platform and pipeline have also drawn attention from investors seeking the best healthcare stocks in biotech. The corporation continues to expand its AI-driven capabilities, most notably through a collaboration with MIT to advance the Boltz-2 AI model on its BioHive-2 platform. This initiative aims to accelerate molecular discovery and synthesis, potentially shortening the path from discovery to clinical trials. The rollout of Recursion OS 2.0 and new partnerships with biopharma and data science firms further enhance its discovery and development capabilities. Copyright: dolgachov / 123RF Stock Photo Upcoming milestones in 2025 include multiple clinical trial initiations and data readouts, such as REC-617, a CDK7 inhibitor in oncology, and REC-4881 for familial adenomatous polyposis. Following its late 2024 merger with Exscientia, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s oncology pipeline has broadened, with several candidates expected to advance into human studies. While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
39 minutes ago
- Yahoo
Clover Health (CLOV) Achieves Profitability as Medicare Advantage Membership Surges
We recently published . ABC is one of the best healthcare stocks. Clover Health Investments, Corp. (NASDAQ:CLOV) is one of the best healthcare stocks. It is a Medicare Advantage insurer that leverages its AI-powered Clover Assistant platform to improve health outcomes, particularly for chronic conditions such as congestive heart failure. Its PPO-focused model offers broader network access compared to typical HMO plans, aiming to reduce hospitalizations and readmissions through advanced analytics and clinical decision support. In Q2 2025, Clover Health Investments, Corp. (NASDAQ:CLOV) reported a 32% year-over-year increase in Medicare Advantage membership, reaching over 106,000 members. Insurance revenue grew 34% to about $470 million, with adjusted EBITDA and net income both at roughly $17 million, maintaining profitability despite elevated sector-wide medical costs. Clover Assistant has demonstrated measurable impact, including an 18% reduction in hospitalizations and 25% fewer 30-day readmissions for heart failure patients under its care model. The business plans to use these results as a competitive differentiator and is expanding the platform to other risk-bearing organizations. Photo by National Cancer Institute on Unsplash The corporation also improved its Medicare star ratings, with PPO plans projected to rise from 3.5 stars in 2025 to 4.0 stars in 2026, boosting reimbursement potential and market competitiveness. While facing rising costs from supplemental benefits and regulatory changes, Clover Health Investments, Corp. (NASDAQ:CLOV) is pursuing cost-efficiency measures such as renegotiating partnerships and expects these efforts, along with regulatory adjustments, to help ease pressures by 2026. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.